1. Home
  2. BLND vs NGNE Comparison

BLND vs NGNE Comparison

Compare BLND & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$1.56

Market Cap

365.1M

Sector

Technology

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$28.75

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLND
NGNE
Founded
2012
2003
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.1M
327.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BLND
NGNE
Price
$1.56
$28.75
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$4.13
$63.57
AVG Volume (30 Days)
2.8M
145.8K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
58.33
0.93
EPS
N/A
N/A
Revenue
$123,585,000.00
N/A
Revenue This Year
$12.62
N/A
Revenue Next Year
$14.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$12.97
52 Week High
$4.49
$37.27

Technical Indicators

Market Signals
Indicator
BLND
NGNE
Relative Strength Index (RSI) 49.95 66.87
Support Level $1.56 $28.37
Resistance Level $1.69 $29.05
Average True Range (ATR) 0.10 1.84
MACD 0.01 0.10
Stochastic Oscillator 60.66 91.52

Price Performance

Historical Comparison
BLND
NGNE

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: